amt-151
mAbexperimentalADC
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 20, 2022 (NCT05498597)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Folate receptor alphaAGONIST
FOLR1 agonist
Chemistry & pharmacology
- Payload
- unclear
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05498597 | Phase 1 | Dec 20, 2022 | Chris O'Brien Lifehouse, Icon Cancer Center, Multitude Therapeutics Inc., Tigermed Consulting Co., Ltd |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chris O'Brien Lifehouse | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Icon Cancer Center | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Multitude Therapeutics Inc. | For profit | 1 | 1 | 1 | 2022 |
| Tigermed Consulting Co., Ltd | For profit | 1 | 0 | 1 | 2022 |
4 organizations
Page 1 / 1